MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2023.09.008

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2023

Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.

Mascarenhas John, Harrison Claire, Schuler Tammy A, Liassou Djibril, Garretson Marné, Miller Taavy A, Mahadevan Sankar, McBride Ali, Tang Derek, DeGutis Irene S, Abraham Pranav, Kish Jonathan, Feinberg Bruce A, Gerds Aaron T

СтатьяПеревод в очереди

Аннотация

BACKGROUND

There is a lack of established clinical outcomes for patients with myelofibrosis (MF) receiving fedratinib following ruxolitinib failure. This study examined real-world patient characteristics, treatment patterns, and clinical outcomes of patients with MF treated with fedratinib following ruxolitinib failure in US clinical practice.

PATIENTS AND

METHODS

This retrospective patient chart review included adults with a physician-reported diagnosis of MF, who initiated fedratinib after discontinuing ruxolitinib. Descriptive analyses characterized patient characteristics, clinical outcomes, and treatment patterns from MF diagnosis through ruxolitinib and fedratinib treatment.

RESULTS

Twenty-four physicians abstracted data for 150 eligible patients. Approximately 55.3% of the patients were male, 68.0% were White, and median age at MF diagnosis was 68 (range, 35-84) years. Median duration of ruxolitinib therapy was 7.6 (range, 0.7-65.5) months. At initiation of fedratinib, 88.0% of patients had palpable spleen and a mean spleen size of 16.0 (standard deviation [SD], 5.9) cm. Spleen size decreased by 19.4% to 13.2 (SD, 7.9) cm at month 3 (P = .0001) and by 53.4% to 7.2 (SD, 7.4) cm at month 6 (P = .01) of fedratinib treatment, respectively. Almost one-third (26.8%) of patients had achieved ≥ 50% spleen reduction by month 6. Mean number of symptoms also decreased significantly at month 3 (P < .0001) and month 6 (P = .01).

CONCLUSION

Fedratinib appears to deliver spleen and symptom benefits in real-world patients with MF previously treated with ruxolitinib.

Для цитирования: Mascarenhas John, Harrison Claire, Schuler Tammy A, Liassou Djibril, Garretson Marné, Miller Taavy A, Mahadevan Sankar, McBride Ali, Tang Derek, DeGutis Irene S, Abraham Pranav, Kish Jonathan, Feinberg Bruce A, Gerds Aaron T. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.. Clinical lymphoma, myeloma & leukemia. 2023. DOI: 10.1016/j.clml.2023.09.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.